COPENHAGEN (Reuters) – Novo Nordisk will prioritise acquisitions that can complement its pipeline of obesity and diabetes drugs rather than buying supply chain companies, the Danish group’s head of business development told Reuters on Friday.
(Reporting by Maggie Fick and Jacob Gronholt-Pedersen, writing by Stine Jacobsen and Louise Rasmussen, editing by Terje Solsvik)
Comments